| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | pac-1 | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | KU 0060648 | CTRPv2 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | -0.0024 | 0.9 |
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | AT13387 | CTRPv2 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | skepinone-L | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0025 | 0.9 |
| mRNA | BRD-A94377914 | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |